Bar-Chama, Natan
Elsheikh, Bakri
Hewamadduma, Channa
Guittari, Carol Jean
Gorni, Ksenija
Mueller, Lutz
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 5 March 2024
Accepted: 29 April 2024
First Online: 16 May 2024
Declarations
:
: Natan Bar-Chama is the recipient of an Investigator-Initiated Study with Genentech, Inc. and F. Hoffmann-La Roche Ltd and has served on a Medical Advisory Board for WINFertility. Bakri Elsheikh received research funding from Alexion Pharmaceuticals, Avidity, Biogen, Genentech, Inc., NMD Pharma, and Pharnext; and served as a consultant for Argenx, Biogen, and Genentech, Inc. Channa Hewamadduma has received speaker and advisory honoraria from Biogen and Roche. His clinical studies are supported by the NIHR BRC Neuroscience centre grant. He conducts patient-reported outcome measures-based natural history studies in SMA via Adult SMA REACH UK funded via Biogen and Roche. Carol Jean Guittari is an employee of Genentech, Inc. and a shareholder of F Hoffmann-La Roche Ltd. Ksenija Gorni and Lutz Mueller are employees and shareholders of F. Hoffmann-La Roche Ltd.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.